Q-omics provides the consensus-scored CASP2 profile across patient tissues and cancer cell-line models. CASP2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, CASP2 is differentially expressed in 16, with the highest sampling consensus in KIRP. Additionally, CASP2 protein abundance shows 22,538 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, KIRP, and LSCC as cancer lineages where CASP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CASP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CASP2 survival associations across molecular data types. CASP2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CASP2 RNA expression–survival associations across cancer types. High CASP2 expression shows unfavorable associations in KICH, ACC, MESO, LIHC and LGG, but favorable associations in OV. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for CASP2 RNA expression.
This table summarizes CASP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CASP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CASP2 shows higher tumor expression in KIRP, BLCA, COAD, HNSC, KIRC and STAD. The KIRP box plot shows higher CASP2 RNA expression in tumor versus normal tissue (log2 FC = +1.692, t-test p < 0.001).
This table shows molecular features associated with CASP2 in patient tissues and cancer cell lines. In patient samples, CASP2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CASP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
